Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 52 Weeks in Adult and Adolescent Subjects with Perennial Allergic Rhinitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Fluticasone furoate (Primary)
- Indications Perennial allergic rhinitis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 01 Aug 2021 This study has been completed in Spain, according to European Clinical Trials Database record.
- 05 Nov 2010 New trial record.